Vertex backs out of agreement with CRISPR Therapeutics for stem cell therapy candidate in diabetes
08 Jan 2024
Cell TherapyGene TherapyLicense out/in
Vertex Pharmaceuticals’ subsidiary ViaCyte is backing out of one of its collaborations with CRISPR Therapeutics on gene-edited stem cell therapies for diabetes.
CRISPR said Monday that ViaCyte has decided to opt-out of a co-development and co-commercialization agreement for CTX211, its beta cell replacement therapy “that is transplanted into patients in a device and intended to produce insulin in a glucose-dependent manner.” While CRISPR in February will wholly own the candidate again, ViaCyte will be paid a royalty on future sales.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.